281 related articles for article (PubMed ID: 25143485)
1. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.
Besancenot R; Roos-Weil D; Tonetti C; Abdelouahab H; Lacout C; Pasquier F; Willekens C; Rameau P; Lecluse Y; Micol JB; Constantinescu SN; Vainchenker W; Solary E; Giraudier S
Blood; 2014 Sep; 124(13):2104-15. PubMed ID: 25143485
[TBL] [Abstract][Full Text] [Related]
2. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
[TBL] [Abstract][Full Text] [Related]
3. Activation of Janus kinase/signal transducers and activators of transcription pathway involved in megakaryocyte proliferation induced by vanadium resembles some aspects of essential thrombocythemia.
Gonzalez-Villalva A; Piñon-Zarate G; Falcon-Rodriguez C; Lopez-Valdez N; Bizarro-Nevares P; Rojas-Lemus M; Rendon-Huerta E; Colin-Barenque L; Fortoul TI
Toxicol Ind Health; 2016 May; 32(5):908-18. PubMed ID: 24442345
[TBL] [Abstract][Full Text] [Related]
4. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
5. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
[TBL] [Abstract][Full Text] [Related]
6. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.
Ng AP; Kauppi M; Metcalf D; Hyland CD; Josefsson EC; Lebois M; Zhang JG; Baldwin TM; Di Rago L; Hilton DJ; Alexander WS
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):5884-9. PubMed ID: 24711413
[TBL] [Abstract][Full Text] [Related]
7. Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.
Marty C; Chaligné R; Lacout C; Constantinescu SN; Vainchenker W; Villeval JL
J Biol Chem; 2009 May; 284(18):11781-91. PubMed ID: 19261614
[TBL] [Abstract][Full Text] [Related]
8. Involvement of prolonged ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line.
Matsumura I; Nakajima K; Wakao H; Hattori S; Hashimoto K; Sugahara H; Kato T; Miyazaki H; Hirano T; Kanakura Y
Mol Cell Biol; 1998 Jul; 18(7):4282-90. PubMed ID: 9632812
[TBL] [Abstract][Full Text] [Related]
9. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.
Rouyez MC; Boucheron C; Gisselbrecht S; Dusanter-Fourt I; Porteu F
Mol Cell Biol; 1997 Sep; 17(9):4991-5000. PubMed ID: 9271377
[TBL] [Abstract][Full Text] [Related]
10. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
Milosevic Feenstra JD; Nivarthi H; Gisslinger H; Leroy E; Rumi E; Chachoua I; Bagienski K; Kubesova B; Pietra D; Gisslinger B; Milanesi C; Jäger R; Chen D; Berg T; Schalling M; Schuster M; Bock C; Constantinescu SN; Cazzola M; Kralovics R
Blood; 2016 Jan; 127(3):325-32. PubMed ID: 26423830
[TBL] [Abstract][Full Text] [Related]
11. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.
Taksin AL; Couedic JP; Dusanter-Fourt I; Massé A; Giraudier S; Katz A; Wendling F; Vainchenker W; Casadevall N; Debili N
Blood; 1999 Jan; 93(1):125-39. PubMed ID: 9864154
[TBL] [Abstract][Full Text] [Related]
12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
14. JAK and MPL mutations in myeloid malignancies.
Tefferi A
Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
[TBL] [Abstract][Full Text] [Related]
15. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
16. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.
Broudy VC; Lin NL
Cytokine; 2004 Jan; 25(2):52-60. PubMed ID: 14693160
[TBL] [Abstract][Full Text] [Related]
17. Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
Millecker L; Lennon PA; Verstovsek S; Barkoh B; Galbincea J; Hu P; Chen SS; Jones D
Cancer Genet Cytogenet; 2010 Feb; 197(1):1-7. PubMed ID: 20113830
[TBL] [Abstract][Full Text] [Related]
18. The TPO/c-MPL pathway in the bone marrow may protect leukemia cells from chemotherapy in AML Patients.
Dong-Feng Z; Ting L; Yong Z; Cheng C; Xi Z; Pei-Yan K
Pathol Oncol Res; 2014 Apr; 20(2):309-17. PubMed ID: 24085601
[TBL] [Abstract][Full Text] [Related]
19. Autocrine role of angiopoietins during megakaryocytic differentiation.
Saulle E; Guerriero R; Petronelli A; Coppotelli E; Gabbianelli M; Morsilli O; Spinello I; Pelosi E; Castelli G; Testa U; Coppola S
PLoS One; 2012; 7(7):e39796. PubMed ID: 22792187
[TBL] [Abstract][Full Text] [Related]
20. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]